List view / Grid view
NRG is developing a pipeline of brain-penetrant small molecule inhibitors of the mitochondrial permeability transition pore (mPTP) with potential as first-in-class treatments for Parkinson's disease and motor neuron disease.
A £4.25 million research grant has been awarded seeks to discover meaningful MND treatments within years.
Scientists have identified that the TEX264 protein and associated enzymes protect the genome from damage, which could lead to new anti-ageing and neurodegeneration therapies.
Scientists using a new motor neuron disease (MND) model have shown astrocytes may protect neurons from toxic TDP-43 protein aggregates in the early stages of disease.
MSD and the Francis Crick Institute will work together on a project to identify disease targets for motor neuron disease.
A study has used EEG to investigate the neuron networks that act abnormally in the condition, providing a significant step in the search for treatments.
